EN 1645

(to be used for	RANSMITTAL FORM MAY all correspondence des inition f Pages in This Submission	Application Number Filling Date First Named Inventor Art Unit Examiner Name Attorney Docket Nu	August 28 Zheng Wu 1645 R. Zeman	, 2001	
Amendm A A Extensio Express Informati Certified Documer Reply to Incomple	smittal Form ee Attached ent/Reply fter Final ffidavits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority nt(s) Missing Parts/ te Application leply to Missing Parts nder 37 CFR 1.52 or 1.53	Drawing(s) (Figs. 1 and Licensing-related Paper Petition Petition Petition to Convert to a Provisional Application Power of Attorney, Rechange of Correspond Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table Remarks If the check is missing, or if an reason related to the enclosed from Fulbright & Jaworski Dep	vocation lence Address on CD y additional fees a materials, the Co	After Appe of Ap Appe (Appe Appe Appe Appe Appe Appe A	der 37 CFR 1.16 to 1.21 for an authorized to deduct said fees
Firm Name	SIGN	ATURE OF APPLICANT, A	ATTORNEY, C	OR AGENT	
Signature Printed name	Michael R. Krawzsenek	.P. (Customer No. 32425)	Reg. No.	Te4 000	
I hereby certify th	nat this correspondence is e as first class mail in an e	DERTIFICATE OF TRANS being facsimile transmitted to the envelope addressed to: Commission	MISSION/MAI	sited with the U	nited States Postal Service with Alexandria, VA 22313-1450 or

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Title:

FORMULATION OF ADENOVIRUS FOR GENE THERAPY

Appl. No.:

09/941,296

Applicant:

Wu et al.

Filed:

August 28, 2001

TC/A.U.:

1645

Examiner:

R. Zeman

Docket No.:

INRP:067USD1

Customer No.:

32425

Confirmation No.

6562

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

May 10, 2005

Date

Michael R. Krawzsenek

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SECOND PRELIMINARY AMENDMENT

Sir:

Applicants submit this Second Preliminary Amendment in the above-referenced case.

Consideration of this case in view of the amendments made below is requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2.

Remarks begin on page 8.